Skip to content

Comparative measurement of potential activity limitations in hemophilia and intensified physiotherapy

Comparative measurement of potential activity limitations in hemophilia and intensified physiotherapy - Haemo_Phys_IIT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00038692
Enrollment
10
Registered
2026-03-09
Start date
2026-08-31
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D66

Interventions

Group 1: Patients with severe or moderate hemophilia and a 10-day intensive physiotherapy: examination of joint health before, 1 and 2 weeks post start of physiotherapy and 3 months after intervention

Sponsors

Hämophiliezentrum/Hämostaseologie, Universitätsklinikum, Goethe Universität Frankfurt
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: • Severe or moderate hemophilia A or B (factor VIII/factor IX < 5%) • at least one target joint (knee, ankle, elbow) • continuous factor substitution or Emicizumab therapy

Exclusion criteria

Exclusion criteria: • Acute joint bleeding in last 4 weeks • planned surgical procedures in observation period • severe co-morbidities

Design outcomes

Primary

MeasureTime frame
Joint status/-functionality at 4 timepoints (before, 1 and 2 weeks post physiotherapy start and 3 months post intensive physiotherapy treatment): -physical examination (Hemophilia Joint Health Score) -Motility test (nach Tinetti) -Hemo-FAST questionnaire (ärztlicher Teil) -joint sonography (HEAD-US Score)

Secondary

MeasureTime frame
Patient questionnaires at 4 timepoints (before, 1 and 2 weeks post physiotherapy start and 3 months post intensive physiotherapy treatment): - every day activites (Hemophilia Activity List, ACTIVLIM-Hemo, Hemo-FAST (patient part) - pain (Numeric rating scale) - health-related quality of life (ED-5Q) Furthers data collected from patient records: sex, age Type of Von Willebrand Disease and severity Von Willebrand and Factor VIII laboratory parameters Bleeding anamnesis (Annual bleeding rate, bleeding pattern, target joints) Therapy scheme Joint conditions (replacement/surgical interventions) Co-morbidities

Countries

Germany

Contacts

Public ContactWolfgang Miesbach

Hämophiliezentrum/Hämostaseologie, Universitätsklinikum, Goethe Universität Frankfurt

Wolfgang.miesbach@unimedizin-ffm.de+496963015051

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026